Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

Here, in a longitudinal cohort of 1245 hospital care workers and 146 nursing home residents, the authors find that a large inter-individual variation in anti-spike antibody levels after one dose of BNT162b2mRNA vaccine is partially explained by age, sex, previous exposure, and treatments, while the...

Full description

Bibliographic Details
Main Authors:	João Faro-Viana, Marie-Louise Bergman, Lígia A. Gonçalves, Nádia Duarte, Teresa P. Coutinho, Patrícia C. Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro, Ana Brennand, Lindsay Kosack, Onome Akpogheneta, João M. Figueira, Conceição Cardoso, Ana M. Casaca, Paula M. Alves, Telmo Nunes, Carlos Penha-Gonçalves, Jocelyne Demengeot
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-27761-z

Similar Items

Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up
by: André Weigert, et al.
Published: (2021-12-01)

Post-Vaccinal Encephalitis with Early Relapse after BNT162b2 (COMIRNATY) COVID-19 Vaccine: A Case Report
by: Miguel A. Vences, et al.
Published: (2022-07-01)

Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty<sup>®</sup>)
by: Jürgen Held, et al.
Published: (2021-09-01)

AVP deficiency (central diabetes insipidus) following immunization with anti-COVID-19 BNT162b2 Comirnaty vaccine in adolescents: A case report
by: Cristina Partenope, et al.
Published: (2023-04-01)

Rhabdomyolysis Following Administration of Comirnaty®
by: Catarina Elias, et al.
Published: (2021-08-01)

Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])
by: Masaru Ando, et al.
Published: (2022-11-01)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
by: Michele Gringeri, et al.
Published: (2021-09-01)

Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report
by: Ryo Kaimori, et al.
Published: (2022-10-01)

Changes in Local and Systemic Adverse Effects following Primary and Booster Immunisation against COVID-19 in an Observational Cohort of Dutch Healthcare Workers Vaccinated with BNT162b2 (Comirnaty<sup>®</sup>)
by: Christiaan Serbanescu-Kele Apor de Zalán, et al.
Published: (2023-12-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
by: Waldemar Rastawicki, et al.
Published: (2023-04-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
by: Letícia Carrijo Masson, et al.
Published: (2023-06-01)

The rare DRB1*04:08-DQ8 haplotype is the main HLA class II genetic driver and discriminative factor of Early-onset Type 1 diabetes in the Portuguese population
by: Iris Caramalho, et al.
Published: (2024-01-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
by: Sascha Hein, et al.
Published: (2021-12-01)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
by: Cheng Siang Tan, et al.
Published: (2022-09-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022-06-01)

Rhabdomyolysis after COVID-19 Comirnaty Vaccination: A Case Report
by: Veerle J. Ruijters, et al.
Published: (2022-11-01)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
by: R. Gurion, et al.
Published: (2022-06-01)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
by: Elizabeth K. Graydon, et al.
Published: (2023-08-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Extended interval BNT162b2 vaccination enhances peak antibody generation
by: Helen Parry, et al.
Published: (2022-01-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
by: Sabina Zurac, et al.
Published: (2022-07-01)

A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
by: Esther Saiag, et al.
Published: (2021-12-01)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
by: Lorenzo Azzi, et al.
Published: (2022-01-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023-01-01)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
by: Natalia Vargas-Herrera, et al.
Published: (2022-01-01)